The Latest Breaking News from Shingles

It’s easy to brush off a leaky faucet or a flickering light as “no big deal.” But some small repairs can quickly spiral into major disasters overnight. What starts as a minor inconvenience can turn into expensive home damage, safety hazards, or even insurance headaches. Homeowners often delay these fixes…

Homeowners often want to save money by tackling roof repairs themselves. It sounds simple—grab a ladder, some tools, and fix that leak or replace a shingle. But DIY roof repairs can be more dangerous than they seem. Every year, thousands of people end up in the emergency room after attempting…

The idea that you can “catch” shingles is one of the more common misconceptions I hear from patients who arrive worried they’ve got it. Often, they’ve recently been near a child with chickenpox or someone else with shingles, and are understandably anxious they’ve picked it up.

Two countries, two different approaches to protecting children from chickenpox. While the UK prepares to introduce a combined vaccine covering measles, mumps, rubella and chickenpox (MMRV) in a single jab, the US is moving in the opposite direction – restricting parents’ ability to choose that same combination for their youngest…

Roofing leaks can start off tiny—almost invisible to the naked eye. But if left unchecked, they quickly become a homeowner’s nightmare. What begins as a drip can turn into thousands of dollars in damage, threaten your home’s structure, and create health risks. Small leaks are easy to ignore, especially if…

Adults vaccinated against shingles had an 18 per cent lower risk of serious heart problems, the analysis found.

IN FULL

Vaccination has increasingly been seen as an effective measure for the prevention, not only of specific infections, but of cardiovascular disease

First global systematic review finds vaccine associated with 18% lower risk of stroke or heart attack in adults

Learn how to choose the best roof restoration materials for Perth homes. Compare metal, tiles, coatings, and slate by cost, climate fit, and durability.

Dynavax Technologies Corporation (NASDAQ:DVAX) announced topline results from Part 1 of its randomized, observer-blinded, and active-controlled Phase 1/2 clinical trial of Z-1018, a shingles vaccine candidate, head-to-head versus Shingrix in participants aged 50 to 69 years on Thursday.